<DOC>
	<DOCNO>NCT00735852</DOCNO>
	<brief_summary>This single-centre , open-label , within patient comparison study assess efficacy safety Decapeptyl SR administer combination Livial treatment woman chronic cyclical pelvic pain . This 2 year period 6 month post treatment follow . The study aim recruit 40 patient .</brief_summary>
	<brief_title>Decapeptyl SR With Livial Add Back Therapy Management Chronic Cyclical Pelvic Pain Pre Menopausal Women</brief_title>
	<detailed_description>A screening visit , perform write informed consent obtain patient . In addition patient 's medical history check , vital sign record , pain general health questionnaire complete , blood sample collect prior concomitant medication note . Bone density determine use DEXA scan perform interval screen baseline visit . One month screen visit , patient return clinic baseline visit . At visit physical examination urine pregnancy test perform , vital sign measure , specific validate questionnaire pain endometriosis relate health complete symptom oestrogen deficiency document . Patients still consider eligible trial receive injection Decapeptyl SR 11.25 mg , dispense sufficient Livial 2.5 mg tablet last next study visit . Patients return repeat Decapeptyl SR injection every 3 month Month 21 time last Decapeptyl SR injection administer . At visit patient also dispense supply Livial . Follow−up assessment perform treatment period 3 , 6 , 12 , 18 24 month baseline visit . A final follow−up assessment conduct 6 month stop treatment . At follow−up visit specific validate questionnaire pain endometriosis relate health collect symptom oestrogen deficiency note . Physical examination , vital sign , bone density assessment haematology biochemistry analysis repeat select timepoints . Health economic data collect study visit .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>age 18 45 year inclusive clinical diagnosis chronic cyclical pelvic pain least 6 month duration ( without evidence endometriosis ) investigation possible endometriosis within three year prior screen visit regular menstrual cycle ( 2442 day ) 3 month prior screen treatment LHRHa indicate must able understand willing comply requirement protocol treat LHRHa within 6 month prior screen treat danazol , gestrinone cyproterone acetate within 6 month prior screen use cyclical progesterone combine oral contraceptive within one full menstrual cycle prior screen treat medication analgesic within 3 month prior screen continuous acyclical pelvic pain know metabolic bone disease abnormal full blood count liver renal function screen within 6 month unexplained vaginal bleed bone mineral density age adjust T Score 2 screen visit . medical condition abnormality would impact safety efficacy study treatment receive treatment coumarin indanedione derivative know contraindication allergy hypersensitivity test compound pregnancy lactation planning pregnancy within 31 month screen child bear potential unwilling use adequate barrier contraception duration study receive investigational drug therapy within 30 day prior study previously enter study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>endometriosis</keyword>
	<keyword>chronic cyclical pelvic pain</keyword>
</DOC>